Document is current
Any future updates will be listed below
-
Authors
Sawalha, Y. https://orcid.org/0000-0001-6355-3671
Sarosiek, S. https://orcid.org/0000-0002-0075-6735
Welkie, R. L.
Seif, S.
Thapa, S.
Zanwar, S. https://orcid.org/0000-0001-5074-8453
Cahill, K.
Treitman, R.
Shah, H.
Arora, S.
Pongas, G.
Winter, A.
Major, A. https://orcid.org/0000-0001-7261-1335
Riedell, P. A. https://orcid.org/0000-0003-2719-0580
Palomba, M. L. https://orcid.org/0000-0001-5099-9156
Kapoor, P. https://orcid.org/0000-0002-4342-364X
Grajales-Cruz, A.
Shain, K. H.
Thomas, S. K.
Castillo, J. J. https://orcid.org/0000-0001-9490-7532
- License Information
-
More Information
Article History
Received: 31 January 2025
Revised: 11 March 2025
Accepted: 27 March 2025
First Online: 15 April 2025
Competing interests
: A.G.C. reports honoraria from Janssen, Sanofi, Cellectar, Amgen, Bristol Myers Squibb, and Pfizer. A.W. has consulted for BeiGene, BTG Pharmaceuticals, AstraZeneca, and ADC Therapeutics. G.P. is a shareholder of Crispr Therapeutics and equity holder of Mevox Ltd and reports consultancy with ADC Therapeutics. J.J.C. received research funding from Abbvie, AstraZeneca, Beigene, Cellectar, Loxo, and Pharmacyclics, and consulting fees from Abbvie, AstraZeneca, Beigene, Cellectar, Janssen, Loxo, Mustang Bio, Nurix, and Pharmacyclics. K.H.S. reports honoraria from Amgen, Bristol Myers Squibb, Janssen, Adaptive, Sanofi, Regeneron, and Takeda, and research funding to the institution from AbbVie and Karyopharm, outside the submitted work. PAR reports serving as a consultant and/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Pfizer, CVS Caremark, Genmab, BeiGene, Janssen, Pharmacyclics, and Genentech/Roche. Honoraria from Adaptive Biotechnologies. Research support from BMS, Kite Pharma, Novartis, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech/Roche, Cellectis, Cargo Therapeutics, and Tessa Therapeutics. P.K. is the principal investigator of trials for which Mayo Clinic has received research funding from Amgen, Regeneron, Bristol Myers Squibb, Loxo Pharmaceuticals, Ichnos, Karyopharm, Sanofi, AbbVie and GlaxoSmithKline. Prashant Kapoor has received honorarium from Keosys and served on the Advisory Boards of BeiGene, Mustang Bio, Janssen, Pharmacyclics, X4 Pharmaceuticals, Kite Pharma, Oncopeptides, Ascentage, Angitia Bio, GlaxoSmithKline, Sanofi and AbbVie. SS received research funds or honoraria from Beigene, Cellectar, and ADC Therapeutics. ST received research funding from Ascentage Pharma, BMS, Genentech, Cellectar Biosciences, and Abbvie and has consulted for Cellectar Biosciences. YS received research funding from BeiGene, Genmab, and AbbVie and has consulted for ADC, Genmab, and Genentech.
